• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virol J . SARS-CoV2 mutations and impact on mortality: observational study in a sub-saharan Africa hospital

tetano

Editor, Senior Moderator
Virol J


. 2023 Mar 30;20(1):56.
doi: 10.1186/s12985-023-02014-1.
SARS-CoV2 mutations and impact on mortality: observational study in a sub-saharan Africa hospital


Jean-Robert Makulo[SUP] 1 [/SUP], Roger Wumba[SUP] 2 [/SUP], Madone Ndona Mandina[SUP] 2 [/SUP], Placide Mbala[SUP] 2 3 4 [/SUP], Adrienne Amuri Aziza[SUP] 2 3 [/SUP], Yannick Mayamba Nlandu[SUP] 2 [/SUP], Benjanmin Kabwe[SUP] 2 5 [/SUP], Donatien Mangala[SUP] 2 [/SUP], Ben Izizag Bepouka[SUP] 2 [/SUP], Jerome Ossam Odio[SUP] 2 [/SUP], Murielle Longokolo[SUP] 2 [/SUP], Eric Mukenge[SUP] 2 [/SUP], Guyguy Kamwiziku[SUP] 2 [/SUP], Eddy Lusamaki Kingand[SUP] 2 [/SUP], Constantin Bashengezi[SUP] 5 [/SUP], Gilbert Kabanda[SUP] 2 5 [/SUP], Benjamin Longo-Mbenza[SUP] 2 5 [/SUP]



Affiliations

Abstract

Background: One year after the coronavirus disease 2019 (COVID-19) pandemic, the focus of attention has shifted to the emergence and spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs). The aim of the study was to assess the frequency of VOCs in patients followed for COVID-19 at Kinshasa university hospital (KUH) during the 3rd and 4th waves of the pandemic in Kinshasa. Hospital mortality was compared to that of the first two waves.
Method: The present study included all patients in whom the diagnosis of SARS-CoV-2 infection was confirmed by the polymerase chain reaction (PCR). The laboratory team sequenced a subset of all SARS-CoV-2 positive samples with high viral loads define as Ct < 25 to ensure the chances to generate complete genome sequence. RNA extraction was performed using the Viral RNA Mini Kit (Qiagen). Depending on the platform, we used the iVar bioinformatics or artic environments to generate consensus genomes from the raw sequencing output in FASTQ format.
Results: During the study period, the original strain of the virus was no longer circulating. The Delta VOC was predominant from June (92%) until November 2021 (3rd wave). The Omicron VOC, which appeared in December 2021, became largely predominant one month later (96%) corresponding the 4th wave. In-hospital mortality associated with COVID-19 fell during the 2nd wave (7% vs. 21% 1st wave), had risen during the 3rd (16%) wave before falling again during the 4th wave (7%) (p < 0.001).
Conclusion: The Delta (during the 3rd wave) and Omicron VOCs (during the 4th wave) were very predominant among patients followed for Covid-19 in our hospital. Contrary to data in the general population, hospital mortality associated with severe and critical forms of COVID-19 had increased during the 3rd wave of the pandemic in Kinshasa.

Keywords: DR Congo; Delta; Kinshasa; Omicron; SARS-CoV-2.
 
Back
Top Bottom